Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)
Fri, Jul 20 2018
STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.
* HENRIK STENQVIST IS JOINING SOBI AS NEW CHIEF FINANCIAL OFFICER
* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Still’s disease.
Feb 22 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.
* SAYS SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.